We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fus-1 Gene May Be Drug Target

By Biotechdaily staff writers
Posted on 31 May 2005
Researchers working with the nematode C elegans as a model organism have found that cells in mutants lacking the fus-1 gene fuse incorrectly. More...
These results imply that this gene may be a target for drugs designed to enhance organ regeneration by stem cells, prevent the progression of cancer, or control fertility.

Fus-1 encodes the e subunit of vacuolar ATPase (V-ATPase). It is localized to the apical plasma membrane in all epidermal cells potentiated to undergo fusion, whereas it is virtually undetectable in nonfusing seam cells. Investigators at the University of California, Santa Barbara (USA) reported in the May 2005 issue of Developmental Cell that the fus-1 gene was essential to repress fusion of epidermal cells in C elegans. In mutants lacking fus-1, all epidermal cells, except the lateral seam cells, inappropriately fused into a single large syncytium (a multinucleated mass of cytoplasm not separated into individual cells). This hyperfusion required EFF-1, an integral membrane protein essential for fusion of epidermal cells into discrete syncytia.

Senior author Dr. Joel H. Rothman, professor of molecular, cellular, and developmental biology at the University of California, Santa Barbara, said, "When a cell fuses with others, it loses its individuality, but it can also adopt a new career, either productive, as when stem cells regenerate organs, or sinister, as in cancer metastasis.”

Dr. Rothman and his colleagues concluded that their findings raised the possibility of manipulating cell fusion by altering V-ATPase activity.



Related Links:
University of California, Santa Barbara

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Multi-Chamber Washer-Disinfector
WD 390
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.